Comprehensive imaging and quantification of blood flow for investigating ocular diseases without additional contrast agent

项目概要/摘要 物理科学公司(PSI)与纽约大学医学院合作 提出开发一种用于表征视网膜形态的新型眼科成像平台， 监测眼部血流异常。该平台将结合联合收割机的非侵入性测量， 视网膜/脉络膜结构和眼血流的光学相干断层扫描（OCT）和宽， 使用线扫描多普勒血流仪（LSDF）进行现场半定量全局血流可视化。的 在同一成像平台内组合这两种成像模态 评估视网膜和脉络膜中的血流。这个新的成像平台将使成像 在具有正常视力或患有各种视网膜疾病的动物和人类受试者中进行的研究。既往PSI 在开发先进的眼科成像系统方面的经验以及我们合作者的专业知识 将充分利用眼科的优势，以确保这一重要的研发计划取得成功。 在第一阶段计划期间，将通过对正常和患病啮齿动物进行成像进行可行性研究 模型使用台式仪器。将制造和测试临床原型仪器 在纽约大学患者人群中进行II期临床试验，以突出血流动力学视网膜生物标志物。我们 选择专注于致盲的主要原因，包括年龄相关性黄斑 糖尿病视网膜病变（DR）和青光眼的临床应用，以证明我们的新的 系统我们将招募健康个体以设定参考，并招募患有AMD、DR和青光眼的受试者， 疾病严重程度的范围很广。在所有这些条件下，记录体内血流的能力将 提供新的信息，开辟新的诊断和治疗途径。

Project Summary/Abstract Physical Sciences Inc. (PSI) in collaboration with New York University (NYU) School of Medicine proposes to develop a novel ophthalmic imaging platform for characterizing retinal morphology and monitoring ocular blood flow abnormalities. This platform will combine non-invasive measurements of retina/choroid structure and ocular blood flow based on optical coherence tomography (OCT) and wide- field semi-quantitative global flow visualization using line-scanning Doppler flowmetry (LSDF). The combination of these two imaging modalities within the same imaging platform enables comprehensive assessment of blood flow in the retina and choroid. This novel imaging platform will enable imaging studies in animals and human subjects with normal vision or with various retinal diseases. Prior PSI experience in developing advanced ophthalmic imaging systems coupled with our collaborators' expertise in Ophthalmology will be leveraged to ensure the successful outcome of this important R&D program. A feasibility study will be performed during the Phase I program by imaging normal and diseased rodent models using a benchtop instrument. A clinical prototype instrument will be manufactured and tested clinically in Phase II in the NYU population of patients to highlight hemodynamic retinal biomarkers. We choose to focus on diseases that are the leading causes of blindness including, age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma to demonstrate the clinical utility of our novel system. We will recruit healthy individuals to set a reference, and subjects with AMD, DR, and glaucoma at a wide range of disease severity. In all of these conditions, the ability to record in vivo blood flow will provide novel information that will open new diagnostic and treatment avenues.